-transparent.png){kind=logo}
In order to determine if different physicochemical properties exist among antihormone-receptor complexes, we have compared the interaction of the antiprogestin RU486 with progesterone receptor (PR) versus the triphenylethylene antiestrogen H1285 (4-(N,N-diethyl-aminoethoxy)-4'-methoxy-alpha-(p-hydroxyphenyl-alp ha'- ethylstilbene] with estrogen receptor (ER) from rabbit uterine tissue. Contrary to other reports, we observed no difference in the sedimentation properties of transformed PR (4S) when bound by the antagonist RU486 versus the progesterone agonist R5020 in either cytosol or DEAE partially-purified receptor preparations analyzed on sucrose gradients containing 0.3 M KCl. In addition, we found no difference in the sedimentation properties of these receptor preparations in the presence of 10 mM sodium molybdate: the nontransformed RU486-PR and nontransformed R5020-PR both sedimented as a 6S species. These same results were obtained when the receptor preparation and gradient analysis were performed in the absence of monothioglycerol. Likewise, there was no change in the sedimentation properties of the transformed PR when the receptor, partially purified in the absence of molybdate, was analyzed on sucrose gradients containing 10 mM sodium molybdate to prevent receptor alteration during centrifugation. From DNA-cellulose assays performed with partially purified PR in the absence of molybdate we determined that the 4S form of R5020-PR and RU486-PR is transformed receptor; whereas in the presence of molybdate, the 6S species is nontransformed. In contrast, we found a different pattern of sedimentation when comparing transformed antiestrogen-receptor complexes with transformed estrogen-receptor complexes. In this case, transformed H1285-ER sedimented as 6S and estradiol-ER sedimented as 4S. We conclude from these experiments that these two antihormones, RU486 and H1285, may have different mechanisms of action in their antagonism of steroid hormone action. Antiestrogen stabilizes the salt-transformed ER as a dimer while antiprogestin appears to permit dissociation of the oligomeric form of the receptor to the monomeric form.
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
March 1987,
Cancer research,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
July 1985,
Cancer research,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
December 1980,
Endocrinology,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
February 1990,
Biochemistry,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
August 1992,
Biochimica et biophysica acta,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
January 1978,
Birth defects original article series,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
March 2000,
Breast cancer research and treatment,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
January 1986,
European journal of gynaecological oncology,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
September 1985,
Molecular and cellular biology,
J W Turner, and
M F Ruh, and
D T Ward, and
T S Ruh
May 1992,
Molecular biology of the cell,
